DAFTAR PUSTAKA

Agus, R., Ahmad, A., Massi, M. N., Handayani, I., & Karim, H. 2019. Cloning and characterization of Rv1980c gene encoding MPT64 Protein from *Mycobacterium tuberculosis* as a new candidate vaccine of tuberculosis. *Journal of Physics: Conference Series.* 1341(3): 1-12

Bafica, A., Morales, S., Eto, C., Souza, N., Nogueira, L., Riley, L., & Mansur, D. 2015. A mycobacterial lectin promotes bacilli adhesion to macrophages and influences pathogen growth during infection (INM3P.409). *The Journal of Immunology.* 194(1 Supplement): 127.14-127.14

Buchari. 2019. Uji Serologi pada Penderita Tuberkulosis Aktif. *Jurnal Kedokteran Nanggroe Medika.* 2(4): 18-26.

Cernuschi, T., Malvolti, S., Nickels, E., & Friede, M. 2017. Bacillus Calmette-Guérin (BCG) vaccine: A global assessment of demand and supply balance. *Vaccine.* 36(4): 498–506

Churchyard, G., Kim, P., Shah, N. S., Rustomjee, R., Gandhi, N., Mathema, B., Dowdy, D., Kasmar, A., & Cardenas, V. 2017. What We Know about Tuberculosis Transmission: An Overview. *Journal of Infectious Diseases.* 216 (Suppl 6): 629–635.

Dinas Kesehatan Sulawesi Selatan. 2018. Profil Kesehatan Sulawesi Selatan Tahun 2017. Dinas Kesehatan Provinsi Sulawesi Selatan: Makassar.

Dewi, I. P. 2017. Metode Pemberian dan Sistem Penghantaran Peningkat Imunogenisitas Vaksin Dna. *Scientia : Jurnal Farmasi Dan Kesehatan.* 7(2): 96.

Dockrell, H. M., & Smith, S. G. 2017. What Have we Learnt About BCG Vaccination in The Last 20 Years? *Frontiers in Immunology.* 8(1): 1-10

Farajnia, S., Ansarin, K., & Sahebi, L. 2019. Effectiveness of Bacillus Calmette–Guerin Vaccination History on Pulmonary Tuberculosis Symptoms. *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases.* 17: 1-3

Gan, S. D., & Patel, K. R. 2013. Enzyme immunoassay and enzyme-linked immunosorbent assay. *Journal of Investigative Dermatology.* 133(9): 1–3

Gorish, B.M.T., Saleh, F.M, Mohammed, F.A., Ahmed, S.R., Yousif, R.A., MI, M., 2018. Screening of BCG Vaccine Efficacy among Healthy Vaccinated Adults in Khartoum, Sudan. *Mycobacterial Diseases*. 08(04): 1-5

Hudu, S. A., Shinkafi, S. H., & Umar, S. 2016. An overview of recombinant vaccine technology, adjuvants and vaccine delivery methods. *International Journal of Pharmacy and Pharmaceutical Sciences*. 8(11): 19-24.

Hunter, R. L. 2018. The Pathogenesis of Tuberculosis: The Early Infiltrate of Post-Primary (adult pulmonary) Tuberculosis: A Distinct Disease Entity. *Frontiers in immunology*. 9: 2108.

Hunter, R., & Actor, J. 2019. The Pathogenesis of Post-Primary Tuberculosis. A Game Changer for Vaccine Development. *Tuberculosis Churchill Livingstone Journal*. 116: 114-117.

Ipandi, I., Sa'adi, A., & Sudjarwo, S. 2019. Verifikasi Metode ELISA (Enzym Linked Immunosorbent Assay) Untuk Penentuan Kadar AMH (Anti Mullerian Hormone). *Jurnal Surya Medika*. 5(1): 201–208.

J. Sambrook i D. W. Russell. 2001. "*Molecular cloning : a laboratory manual, III.*" Edisi ketiga. New York*:* Cold Spring Harbor Laboratory Press.

Kaufmann, Stefan H.E., Weiner, January., Von Reyn,, dan C. Fordham. 2017. Novel approaches to tuberculosis vaccine development. *International Journal of Infectious Diseases.* 56: 263-267.

Kementerian Kesehatan RI. 2018. *InfoDatin Tuberculosis*. Kementerian Kesehatan RI. Jakarta.

Kolbe, K., Veleti, S. K., Reiling, N., & Lindhorst, T. K. 2019. Lectins of mycobacterium tuberculosis –rarely studied proteins. *Beilstein Journal of Organic Chemistry*. *15*. 1–15.

Lamichhane, S. R. A. M., & Milic, N. 2018. *Mycobacterium tuberculosis: Gene and Genome analysis Mycobacterium tuberculosis: GENE AND GENOME ANALYSIS.* Asian Journal of Microbiology and Biotechnology. 3(1): 24-33.

Liang, Y., Zhang, X., Xiao, L., Bai, X., Wang, X., Yang, Y., & Wu, X. 2016. *Immunogenicity and therapeutic effects of pVAX1-rv1419 DNA from Mycobacterium tuberculosis*. Current Gene Therapy. 16(4): 249-255.

Li, F., Kang, H., Li, J., Zhang, D., Zhang, Y., Dannenberg, A. M., Zhu, B. 2017. Subunit Vaccines Consisting of Antigens from Dormant and Replicating Bacteria Show Promising Therapeutic Effect against Mycobacterium Bovis BCG Latent Infection. *Scandinavian Journal of Immunology*. 85(6): 425-432.

Lopes, F. H. A., De Assis, L. C., Da Justa Pires Neto, R., Botelho, K. P., Sá, K. M., Frota, C. C., Freitas, M. V. C. 2013. Serum levels of interleukin-6 in contacts of active pulmonary tuberculosis. *Jornal Brasileiro de Patologia e Medicina Laboratorial*, 49(6): 410–414.

Martinez, A. N., Mehra, S., & Kaushal, D. 2013. Role of Interleukin 6 in Innate Immunity to *Mycobacterium tuberculosis* Infection. *Journal of Infectious Diseases*. 207(8): 1253–1261

Martino, M., Lodi, L., Galli, L., & Chiappini, E. 2019. Immune Response to *Mycobacterium tuberculosis*: A Narrative Review. *Frontiers in Pediatrics*. 7: 1-8

Michelsen, S. W., Soborg, B., Diaz, L. J., Hoff, S. T., Agger, E. M., Koch, A., Melbye, M. 2017. The Dynamics of Immune Responses to *Mycobacterium tuberculosis* During Different Stages of Natural Infection: A longitudinal study among Greenlanders. *PLoS ONE*. 12(6): 1-22

National Center for Biotechnology Information (NCBI). 2020. U. S. National Library of Medicine. United State of America.

Nogueira, L., Cardoso, F. C., Mattos, A. M., Bordignon, J., Figueiredo, C. P., Dahlstrom, P., Frota, C. C., Duarte Dos Santos, C. N., Chalhoub, M., Cavada, B. S., Teixeira, H. C., Oliveira, S. C., Barral-Netto, M., & Báfica, A. 2010. *Mycobacterium tuberculosis* Rv1419 encodes a secreted 13 kDa lectin with immunological reactivity during human tuberculosis. *European Journal of Immunology*. 40(3): 744–753.

O'connell, A. K., & Douam, F. 2020. Humanized mice for live-attenuated vaccine. *Journal Vaccines*. 8(1): 1-42.

Parmer, J., Allen, L., & Walton, W. 2018. Tuberculosis: A New Screening Recommendation and an Expanded Approach to Elimination in the United States: A review of risk assessment, testing, and treatment. *The American journal of nursing*. 117(8): 24-34

Prasetyo, E., Astuti, T., Muktiati, N. S., & Arthamin, M. Z. 2019. Immunogenicity Test of ESAT-6/CFP-10 *Mycobacterium tuberculosis* (Indonesian Strain) Recombinant Protein Fusion: TNF-α, IL-17 and CD4+ T Cells Expression in PBMC Culture. *Jurnal Respirologi Indonesia*. 39(3): 160-168.

Qiagen. 2008. *Ni-NTA Spin Kit Handbook-Ni-NTA Spin Kit, Ni-NTA Spin Columns for Manual Automated Purification of His-Tagged Proteins*. Edisi Kedua. Germany: Qiagen.

Romero-Adrian, T. B. 2015. Role of cytokines and other factors involved in the Mycobacterium tuberculosis infection. *World Journal of Immunology*. 5(1): 16.

S., F. A., R. E. T. Buchanan, N. E. Gibbons, and Bergey. 1975. *"Bergey's Manual of Determinative Bacteriology."* Edisi ketujuh. *Taxon*.

Sayin, Z., & Erganis, O. 2013. Diagnosis of Bovine Tuberculosis by PPD-ELISA and Sonication-ELISA. *Israel Journal of Veterinary Medicine*. 68(3): 180–184.

Singh, P. P., & Goyal, A. 2013. Interleukin-6: A potent biomarker of mycobacterial infection. *SpringerPlus*, 2(1): 2-9.

Sumiarsih, T. P., Kajian DNA Rekombinan pada Vaksin DNA dan Vaksin Subunit Protein Study of Recombinant DNA in DNA Vaccines and Protein Subunit Vaccines. *PharmaMedika.* 10(2): 108-128.

Sumiati, T., Sukenda, S., Nuryati, Sri., Lusiastuti, Mariana., Angela M. 2015. Development of ELISA method to detect specific immune response in nile tilapia (O. niloticus) vaccinated against A. hydrophila and S. agalactiae. *J. Ris. Akuakultur*. 10: 243-250.

Susmiarsih, T. P., & Putih, C. 2018. Kajian DNA Rekombinan pada Vaksin DNA dan Vaksin Subunit Protein Study of Recombinant DNA in DNA Vaccines and Protein Subunit Vaccines Tri Panjiasih Susmiarsih. *PharmaMedika*. 10(2): 108–128.

Syafa'ah, I., & Yudhawati, R. 2019. Peran Imunitas Mukosa terhadap Infeksi Mycobacterium Tuberculosis. *Jurnal Respiras.* 2(2): 61-68

Walker, J, M., 1984. *Proteins*. The Human Press Inc.

Whitlow, E., Mustafa, A. S., & Hanif, S. N. M. 2020. An overview of the development of new vaccines for tuberculosis. *Journal Vaccines MDPI AG*. 8: 1-13.

WHO. 2020."*WHO Global Tuberculosis Report 2019.*" Geneva: World Health Organization

WHO. 2020."*WHO Global Tuberculosis Report 2020.*" Geneva: World Health Organization

Wulandari K. E, Y. T., Susanti, R., & Bintari, S. H. 2019. Analisis Perkembangan Titer Antibodi Hasil Vaksinasi Infectious Bronchitis pada Ayam Petelur Strain Hisex Brown. *Life Science*. 8(1): 25–33.

LAMPIRAN

Lampiran 1. Skema kerja

```
┌─────────────────────────────────────────────┐
│  Kriteria Sampel (15 Serum darah TB aktif dan 15  │
│         serum darah orang sehat)              │
└─────────────────────────────────────────────┘
                      ↓
┌─────────────────────────────────────────────┐
│          Penyiapan Protein sMTL-13           │
└─────────────────────────────────────────────┘
                      ↓
┌─────────────────────────────────────────────┐
│    Mengukur Konsentrasi Protein sMTL-13      │
└─────────────────────────────────────────────┘
                      ↓
┌─────────────────────────────────────────────┐
│    *Coating* (Pelapisan) Protein sMTL-13     │
└─────────────────────────────────────────────┘
                      ↓
┌─────────────────────────────────────────────┐
│                 Uji ELISA                    │
└─────────────────────────────────────────────┘
                      ↓
┌─────────────────────────────────────────────┐
│   Analisis Data statistik (*one sample t test*)  │
└─────────────────────────────────────────────┘
                      ↓
┌─────────────────────────────────────────────┐
│                  Hasil                       │
└─────────────────────────────────────────────┘
```

Lampiran 2. Alat

ELISA Mikroplate

Inkubator shaker

Mikropipet


Tabung falcon

Tabung eppendorf

Tip

Rak tabung


ELISA reader

Tabung vakum

Lampiran 3. Bahan

Substrat solution B

Wash solution

Substrat solution A

Standar diluent

Stop solution

Streptavidin HRP

Biotin Conjugate Antibody

Serum orang sehat

Serum penderita TB aktif

PBS pH 7,2

Blocking solution

Protein rekombinan sMTL-13

Lampiran 4. Prosedur kerja

Tahap coating protein

Tahap uji ELISA

Proses pembacaan oleh ELISA reader

Lampiran 5. Tabel Distribusi t (df = 1-41)

Df	Sinifikansi		Df	Siknifikansi	
	0.025	0.05		0.025	0.05
1	12.706	6.314	46	2.013	1.679
2	4.303	2.920	47	2.012	1.678
3	3.182	2.353	48	2.011	1.677
4	2.776	2.132	49	2.010	1.677
5	2.571	2.015	50	2.019	1.676
6	2.147	1.943	51	2.008	1.675
7	2.365	1.8+5	52	2.007	1.675
8	2.306	1.80	53	2.006	1.674
9	2.262	1.863	54	2.005	1.674
10	2.228	1.832	55	2.004	1.673
11	2.201	1.716	56	2.003	1.673
12	2.179	1.792	57	2.002	1.672
13	2.160	1.781	58	2.002	1.672
14	2.145	1.771	59	2.001	1.671
15	2.131	1.763	60	2.000	1.671
16	2.120	1.756	61	2.000	1.670
17	2.110	1.740	62	1.999	1.660
18	2.101	1.744	63	1.998	1.669
19	2.093	1.739	64	1.998	1.669
20	2.086	1.725	65	1.997	1.669
21	2.080	1.721	66	1.997	1.668
22	2.074	1.727	67	1.996	1.668
23	2.069	1.714	68	1.995	1.668
24	2.06.	1.711	69	1.995	1.667
25	2.060	1.718	70	1.994	1.667
26	2.056	1.706	71	1.994	1.667
27	2.052	1.703	72	1.993	1.666
28	2.048	1.701	73	1.993	1.666
29	2.045	1.609	74	1.993	1.666
30	2.042	1.697	75	1.992	1.665
31	2.040	1.696	76	1.992	1.665
32	2.037	1.694	77	1.991	1.665
33	2.035	1.692	78	1.991	1.665
34	2.032	1.691	79	1.990	1.664
35	2.030	1.690	80	1.990	1.664
36	2.028	1.688	81	1.990	1.664
37	2.026	1.687	82	1.989	1.664
38	2.024	1.686	83	1.989	1.663
39	2.023	1.685	84	1.989	1.663
40	2.021	1.684	85	1.988	1.663
41	2.020	1.683	86	1.988	1.663
42	2.018	1.682	87	1.988	1.663
43	2.017	1.681	88	1.987	1.662
44	2.015	1.680	89	1.987	1.662

Lampiran 6. Tabel uji statistik *one sample t test* Uji ELISA

					95% Confidence Interval of the Difference	
One-Sample Test						
	Test Value = 0					
	T	Df	Sig. (2-tailed)	Mean Difference	Lower	Upper
Absorbansi	20.317	29	.000	.0761133	.068451	.083775
Konsentrasi IL 6	12.757	29	.000	79.08400	66.4048	91.7632

Lampiran 7. Kurva OD standar